In 1910, German scientist Paul Ehrlich introduced a groundbreaking concept to the world: chemical compounds could be engineered to interact with unique receptors on disease-causing cells while avoiding interaction with healthy cells.
Over a century later, Antibody Drug Conjugates (ADCs)








